Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

scientific article

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.YGYNO.2016.11.043
P698PubMed publication ID27931751

P50authorFranco MuggiaQ30512486
Leslie BoydQ38801338
John P. CurtinQ38801361
Judith D. GoldbergQ48328661
Bhavana PothuriQ85856253
Stephanie V BlankQ91909560
Amy TierstenQ101403740
Fernanda MusaQ117265819
P2093author name stringXiaochun Li
Huichung T Ling
James L Speyer
P2860cites workCancer statistics, 2013Q27860762
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyQ28258045
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alphaQ28259513
A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinomaQ33330638
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancerQ33331282
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.Q33552740
Targeting hypoxia cell signaling for cancer therapyQ36784388
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cellsQ40483692
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumorsQ40550209
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implicationsQ40585883
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical modelQ42573981
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.Q44276671
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaQ46114146
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerQ46135004
Optimal two-stage designs for phase II clinical trialsQ46412217
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerQ46892024
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaQ48264845
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 studyQ84676387
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialQ87460208
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectirinotecanQ412197
bevacizumabQ413299
ovarian cancerQ172341
P304page(s)279-284
P577publication date2016-12-05
P1433published inGynecologic OncologyQ5625182
P1476titlePhase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
P478volume144

Reverse relations

cites work (P2860)
Q100385888A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
Q38687169Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER.
Q52362144Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Q49788115Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis.
Q92594112Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities
Q99583257Secondary and tertiary ovarian cancer recurrence: what is the best management?
Q96022689Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
Q98164379Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Search more.